Tibet Aim Pharm Inc
SZSE:002826
Relative Value
The Relative Value of one Tibet Aim Pharm Inc stock under the Base Case scenario is 9.77 CNY. Compared to the current market price of 9.19 CNY, Tibet Aim Pharm Inc is Undervalued by 6%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Tibet Aim Pharm Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CN |
Tibet Aim Pharm Inc
SZSE:002826
|
1.8B CNY | 2.2 | 37.5 | 27 | 27 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
716.9B USD | 20 | 116.8 | 57.2 | 65.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.4 | 45.4 | 33.2 | 36.2 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
356.2B USD | 4.2 | 9.3 | 11.4 | 14.9 | ||
US |
Merck & Co Inc
NYSE:MRK
|
321.2B USD | 5.2 | 139.3 | 33.2 | 52.6 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.4 | 140.7 | 225.7 | ||
CH |
Novartis AG
SIX:NOVN
|
180B CHF | 4.3 | 13.4 | 9.8 | 16.2 | ||
CH |
Roche Holding AG
SIX:ROG
|
174.5B CHF | 3 | 15.2 | 8.6 | 10.3 | ||
US |
Pfizer Inc
NYSE:PFE
|
158.8B USD | 2.9 | -513.9 | 12.8 | 20.3 |